Halozyme Therapeutics Inc (HALO)
38.64
+0.84
(+2.21%)
USD |
NASDAQ |
Apr 19, 16:00
38.64
0.00 (0.00%)
After-Hours: 20:00
Halozyme Therapeutics Free Cash Flow: 373.28M for Dec. 31, 2023
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| December 31, 2023 | 373.28M |
| September 30, 2023 | 353.63M |
| June 30, 2023 | 292.79M |
| March 31, 2023 | 263.58M |
| December 31, 2022 | 235.30M |
| September 30, 2022 | 237.55M |
| June 30, 2022 | 290.16M |
| March 31, 2022 | 287.26M |
| December 31, 2021 | 297.98M |
| September 30, 2021 | 264.85M |
| June 30, 2021 | 149.51M |
| March 31, 2021 | 115.93M |
| December 31, 2020 | 52.95M |
| September 30, 2020 | -23.54M |
| June 30, 2020 | -60.14M |
| March 31, 2020 | -89.07M |
| December 31, 2019 | -89.46M |
| September 30, 2019 | -54.81M |
| June 30, 2019 | -43.38M |
| March 31, 2019 | -36.50M |
| December 31, 2018 | -54.16M |
| September 30, 2018 | 90.84M |
| June 30, 2018 | 130.20M |
| March 31, 2018 | 132.24M |
| December 31, 2017 | 132.70M |
| Date | Value |
|---|---|
| September 30, 2017 | -35.90M |
| June 30, 2017 | -65.17M |
| March 31, 2017 | -61.96M |
| December 31, 2016 | -53.52M |
| September 30, 2016 | -54.14M |
| June 30, 2016 | -62.29M |
| March 31, 2016 | -39.60M |
| December 31, 2015 | -39.44M |
| September 30, 2015 | -23.79M |
| June 30, 2015 | -20.02M |
| March 31, 2015 | -44.81M |
| December 31, 2014 | -48.89M |
| September 30, 2014 | -64.29M |
| June 30, 2014 | -63.47M |
| March 31, 2014 | -58.39M |
| December 31, 2013 | -51.64M |
| September 30, 2013 | -52.47M |
| June 30, 2013 | -54.19M |
| March 31, 2013 | -57.62M |
| December 31, 2012 | -65.69M |
| September 30, 2012 | -62.34M |
| June 30, 2012 | -61.36M |
| March 31, 2012 | -43.19M |
| December 31, 2011 | -35.13M |
| September 30, 2011 | -28.77M |
Free Cash Flow Range, Past 5 Years
-89.46M
Minimum
Dec 2019
373.28M
Maximum
Dec 2023
150.23M
Average
235.30M
Median
Dec 2022
Free Cash Flow Benchmarks
| Johnson & Johnson | 17.78B |
| Globus Medical Inc | 165.22M |
| Denali Therapeutics Inc | -370.93M |
| AIM ImmunoTech Inc | -21.85M |
| Protalix BioTherapeutics Inc | -2.467M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 102.35M |
| Cash from Investing (Quarterly) | -8.291M |
| Cash from Financing (Quarterly) | -249.92M |
| Free Cash Flow Per Share (Quarterly) | 0.761 |
| Free Cash Flow to Equity (Quarterly) | 98.13M |
| Free Cash Flow to Firm (Quarterly) | 104.16M |
| Free Cash Flow Yield | 7.20% |